Cambridge Judge Business School Entrepreneurship Centre A Cambridge Judge Business School Accelerate Cambridge White Paper ACCELERATE CAMBRIDGE VENTURES IN THE NEWS Startup spotlights & venture updates: 2018-2020 2 A message from our Venture Team Established in May 2012, Accelerate Cambridge is now celebrating five years of enabling meaningful venture creation. To date, the accelerator has supported 400 entrepreneurs,170 ventures and helped raise £100 million in funding. Our list of inspirational alumni ventures includes: HealX, AlgoDynamix; Hinton Bikes; LIF-Nano Therapeutics; Satavia; Swift DX and Speechmatics. Accelerate Cambridge was described as the "best startup programme in Cambridge," by Dr Tim Guilliams, Founder of Healx and the Co-Founder of Cambridge Rare Diseases. The Accelerator offers a structured approach of three- month programmes that combine entrepreneurship training, regular coaching and mentoring, as well as access to shared workspace. There is no charge and we do not ask for equity from any of the ventures. Startups enter at the Pre-Accelerate stage and, depending on their needs, progress through to Accelerate Star. They can participate for a minimum of three months and up to a maximum of five years. On joining the programme, the teams learn how to pitch their ideas with confidence, craft a fundable and sustainable business plan; raise financial capital and deal with investors. Startup spotlights 4 September 2020 - Media Mentions 9 August 2020 - Media Mentions 9 July 2020 - Media Mentions 9 June 2020 - Media Mentions 9 May 2020 - Media Mentions 10 April 2020 - Media Mentions 10 March 2020 - Media Mentions 11 February 2020 - Media Mentions 11 October 2019 - Media Mentions 12 September 2019 - Media Mentions 13 July 2019 - Media Mentions 13 June 2019 - Media Mentions 14 May 2019 - Media Mentions 15 April 2019 - Media Mentions 16 March 2019 - Media Mentions 17 February 2019 - Media Mentions 18 January 2019 - Media Mentions 18 December 2018 - Media Mentions 19 November 2018 - Media Mentions 20 October 2018 - Media Mentions 21 September 2018 - Media Mentions 21 Santander Universities: news summary 23 4 Startup spotlights Healx: April 2020 spotlight Healx, a biotech firm that was supported by the Entrepreneurship Centre at Cambridge Judge Business School, says it is using its artificial intelligence (AI) platform to develop drug combinations from approved drugs to seek treatments for COVID-19.The Cambridge-based company, which specialises in rare diseases, said combination therapy candidates will be available in May for testing in collaboration with partners. Healx said that the focus on combination therapies, where two or more drugs simultaneously target different aspects of the disease pathology, has the potential to ensure a more effective treatment. Combination therapies are particularly difficult to discover, as it requires detailed analysis of millions of possible pairs from the thousands of drugs on the market. The Healx AI platform, Healnet, analyses biomedical data from multiple sources to predict those combination therapies most likely to succeed. Healx was previously on the Accelerate Cambridge and the SME Growth Challenge programme, now known as the Strategic Business Growth programme. Find out more > Kalium Health: March 2020 spotlight Kalium Health, aims to transform the lives of patients with kidney disease, today announces the completion of a seed investment round of £950,000. The over- subscribed round was led by Cambridge Enterprise with participation from Kidney Research UK, Cambridge Angels and Martlet Capital, the investment arm of Marshall of Cambridge Group. Kalium Health spun out of the University of Cambridge where its work began with grant funding from several sources, including an academic research grant from the charity Kidney Research UK. The company is now working to transform the lives of millions of people worldwide with kidney or heart disease, and to reduce total healthcare costs, by enabling blood electrolyte monitoring by anyone, anytime, anywhere. The first product Kalium Health is developing is a rapid, accurate test for blood potassium concentration based on a tiny drop of finger-prick blood. It will enable patients to seek treatment before complications arise and without the inconvenience, cost and delays associated with current testing methods. The investment will allow the company to accelerate its technology and product development plans. Kalium Health aims to launch its first test as an approved medical device within four years. The team has recently signed an agreement for larger laboratory and office space in Cambridge and has begun recruiting engineers and technicians, planning to double head count from four to eight during the first half of 2020. Spotta: February 2020 spotlight Spotta aims to be the world leader in smart pest detection. Founded by Robert Fryers and Neil D'Souza-Mathew, experts in low power sensor systems and already on their second business together. Their core technology is an ultra-low-power, insect monitoring sensor that can detect infestations early. This allows their customers to intervene and resolve the problems earlier, more cheaply and with less environmental impact. Spotta's Bed Pod system is a revolutionary new way to pre-empt and minimise the damage bed bugs can cause in hotel accommodation. A Pod is placed in each room and, if there are bed bugs present, the hotel's management team get an automated email warning, complete with room number, date and even a photo. This allows them to intervene and resolve the problem before their guests get bitten. Bed Pod is eliminating guest complaints and bad reviews by preventing the bad experience of guests encountering bed bugs from happening in the first place. Spotta is currently on our Accelerate Cambridge programme and was awarded 'Pitch of the night' at Pitch and Judge on 30 January 2020. Read more > ET-traps: January 2020 spotlight ET-traps is a Biotechnology company developing a novel therapeutic tool to be used in diabetes and beyond. The venture was founded by Dr Arjun Jain, who was pursuing his PhD in Reproductive Biochemistry at the University of Cambridge back in 2008. A turning point for ET-traps came in March 2015 when Arjun attended Venture Creation Weekend when he pitched his business idea and won first place. In April 2015, ET-traps (formerly known as Endotraps) joined the Accelerate Cambridge programme. Tony Harris, who was Arjun's mentor during the Accelerate Cambridge programme, said: "This technology has huge potential in treatments but, like all technologies born in university laboratories, it will need to tread the road of extensive clinical trials before it can be proven in the field. If ET-traps can prove the technology in-vivo (in the body) rather than just in-vitro (in the test tube) then their future is assured." Read more > Outfield: July 2019 spotlight Outfield is an innovative platform created by a startup team now participating in Accelerate Cambridge that provides orchard growers with useful data to reduce inputs and improve yields. Outfield uses machine vision techniques to extract features from drone imagery allowing growers to predict yields and improve crop management through blossom mapping, plant health analysis and fruit counting. Outfield were recently awarded £95,000 by InnovateUK for a three year project targeting blossoms early on during apple growing season in order to develop precision application blossom-thinning sprays. The project has found they are able to maximise yields and reduce environmental impacts, adding value to the Outfield orchard platform. Earlier this month, Outfield partnered on a paper with the Innovate UK project consortium, presented by Rob Saunders at the SuproFruit 2019 conference at NIAB EMR. Jim McDougall, co-founder of Outfield, said: "Accelerate 6 Cambridge has been absolutely fantastic. Although we are very good at engineering and our product, it's been great to have an external view to keep us straight on business aspects. The programme has helped to challenge our business proposition and steer us to a commercially successful product. We have made some amazing connections [and] the mentors on the programme have been excellent." Outfield has also submitted projects to EnterpriseTECH as inventors and gained some valuable insights from students, including help with a grant application, realising an unviable product, and developing routes to market. Jim said, "The real challenge now is moving fast enough to take full advantage of the opportunities in front of us. We're gearing up for a funding round, target to close early next year, which will help us grow quickly and get working on orchards around the UK and hopefully around the world." Outfield is also connected with the University of Cambridge Physics and Engineering Departments who are helping to provide machine vision and support. Sano Genetics: September 2019 spotlight Sano Genetics, a venture supported by Accelerate Cambridge, is launching their own DNA sequencing kits. Sano Genetics, formerly known as Heterogeneous, connects people with research in personalised medicine. Sano is different from most direct-to-consumer genetics companies in that it provides participants full control of how their data is used, and emphasises not just providing reports, but also matching people with research projects that are relevant to them. Sano one of the first UK based companies to offer whole genome and whole exome sequencing. Sano has already matched thousands of people to research